Astellas Pharma Stock Performance
| ALPMY Stock | USD 10.08 0.20 1.95% |
The firm shows a Beta (market volatility) of -0.13, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Astellas Pharma are expected to decrease at a much lower rate. During the bear market, Astellas Pharma is likely to outperform the market. At this point, Astellas Pharma has a negative expected return of -0.27%. Please make sure to confirm Astellas Pharma's treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and price action indicator , to decide if Astellas Pharma performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Astellas Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's primary indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Begin Period Cash Flow | 326.1 B | |
| Total Cashflows From Investing Activities | -62.4 B |
Astellas |
Astellas Pharma Relative Risk vs. Return Landscape
If you would invest 1,214 in Astellas Pharma on September 16, 2024 and sell it today you would lose (206.00) from holding Astellas Pharma or give up 16.97% of portfolio value over 90 days. Astellas Pharma is currently producing negative expected returns and takes up 1.6405% volatility of returns over 90 trading days. Put another way, 14% of traded pink sheets are less volatile than Astellas, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Astellas Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Astellas Pharma's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Astellas Pharma, and traders can use it to determine the average amount a Astellas Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1661
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ALPMY |
Estimated Market Risk
| 1.64 actual daily | 14 86% of assets are more volatile |
Expected Return
| -0.27 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.17 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Astellas Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Astellas Pharma by adding Astellas Pharma to a well-diversified portfolio.
Astellas Pharma Fundamentals Growth
Astellas Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Astellas Pharma, and Astellas Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Astellas Pink Sheet performance.
| Return On Equity | 0.0898 | |||
| Return On Asset | 0.0653 | |||
| Profit Margin | 0.09 % | |||
| Operating Margin | 0.17 % | |||
| Current Valuation | 26.19 B | |||
| Shares Outstanding | 1.83 B | |||
| Price To Earning | 25.98 X | |||
| Price To Book | 2.44 X | |||
| Price To Sales | 0.02 X | |||
| Revenue | 1.3 T | |||
| EBITDA | 241.52 B | |||
| Cash And Equivalents | 336.76 B | |||
| Cash Per Share | 184.77 X | |||
| Total Debt | 4.87 B | |||
| Debt To Equity | 0 % | |||
| Book Value Per Share | 861.58 X | |||
| Cash Flow From Operations | 257.44 B | |||
| Earnings Per Share | 0.57 X | |||
| Total Asset | 2.33 T | |||
| Retained Earnings | 941.23 B | |||
| Current Asset | 874.69 B | |||
| Current Liabilities | 383.53 B | |||
About Astellas Pharma Performance
Evaluating Astellas Pharma's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Astellas Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Astellas Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan. ASTELLAS PHARMA operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 14522 people.Things to note about Astellas Pharma performance evaluation
Checking the ongoing alerts about Astellas Pharma for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Astellas Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Astellas Pharma generated a negative expected return over the last 90 days |
- Analyzing Astellas Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Astellas Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Astellas Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Astellas Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Astellas Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Astellas Pharma's pink sheet. These opinions can provide insight into Astellas Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Astellas Pink Sheet Analysis
When running Astellas Pharma's price analysis, check to measure Astellas Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Astellas Pharma is operating at the current time. Most of Astellas Pharma's value examination focuses on studying past and present price action to predict the probability of Astellas Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Astellas Pharma's price. Additionally, you may evaluate how the addition of Astellas Pharma to your portfolios can decrease your overall portfolio volatility.